CIENCIASMEDICASNEWS

miércoles, 7 de octubre de 2026

A novel mineral-organic bone adhesive promotes calvarial bone regeneration in microgravity conditions Roberta Di Carlo, Uzma Mhate, Luigi Mancinelli, Sourabh Boruah, Taiana C. Leite, Xuehui Geng, Michael C. Brown, Afton K. Limberg, Douglas W. Van Citters, Brian J. Hess, George W. Kay & Giuseppe Intini

A novel mineral-organic bone adhesive promotes calvarial bone regeneration in microgravity conditions Roberta Di Carlo, Uzma Mhate, Luigi Mancinelli, Sourabh Boruah, Taiana C. Leite, Xuehui Geng, Michael C. Brown, Afton K. Limberg, Douglas W. Van Citters, Brian J. Hess, George W. Kay & Giuseppe Intini https://www.nature.com/articles/s41526-026-00606-z Microgravity significantly impacts astronaut physiology, causing accelerated bone loss and impairing bone regeneration. As human space exploration expands, effective and minimally invasive bone repair treatments are crucial. In this study, we investigated the regenerative potential of a novel mineral-organic bone adhesive, Tetranite® (TN), compared to the osteoinductive rhBMP2 (Infuse®). We used a critical-size calvarial bone defect model in mice, with half launched on a 60-day mission to the International Space Station and the other half serving as ground controls. Histological and quantitative micro-computed tomography (MicroCT) analyses confirmed that both TN and rhBMP2 promoted bone regeneration in both spaceflight and ground conditions. While both biomaterials were effective, TN’s regenerative effect was more localized to the defect site. Our findings demonstrate that TN implantation effectively promotes calvarial bone regeneration under both microgravity and terrestrial conditions. This suggests its potential as a minimally invasive clinical solution for treating bone fractures during future space missions and on Earth.

The Fifth Transatlantic Exchange in Oncology: Transatlantic Innovations in Cancer Drug Research – A Selection of Key Presentations From the Event

https://www.medscape.com/medicalaffairs/448002.4/media-4?src=0_nl_sm_0&uac=148436CN The Fifth Annual Transatlantic Exchange in Oncology reflects an ongoing collaboration between key scientists, clinicians, and researchers from the Institut Gustave Roussy in Villejuif, France and Dana-Farber Cancer Institute (DFCI) in Boston, USA (supported by L’Institut Servier). This year’s event brought together a global audience with expertise in medical oncology, translational research, and molecular biology to exchange and discuss insights and new developments in the rapidly evolving area of cancer drug research. The event was held in Boston – at the Jimmy Fund Auditorium at DFCI - on March 27, 2026. Prof Eric Fischer from DFCI gave his insights on the day with this short “Expert Commentary” on the program. Prof Toni Choueiri then provides the Welcome Address. This is followed by 4 videos from the day’s events which reflect the depth and diversity of cancer drug research and collaboration across the Atlantic.

FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.